Gavreto® (pralsetinib) – New orphan drug approval
September 7, 2020 - Roche and Blueprint Medicines announced the FDA approval of Gavreto (pralsetinib), for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
Top